Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa
The DOI matches its Crossref record; 25 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the burden and impact of immune reconstitution disease (IRD) associated with tuberculosis (TB) among patients initiating antiretroviral treatment (ART) in sub-Saharan Africa. DESIGN: Retrospective analysis of a study cohort enrolled over 3 years within a community-based ART service in South Africa. METHODS: Patients receiving treatment for TB at the time ART was initiated (n = 160) were studied. Cases of TB-associated IRD during the first 4 months of ART were ascertained. RESULTS: The median baseline CD4 cell count was 68 cells/microl [interquartile range (IQR), 29-133 cells/microl) and ART was initiated after a median of 105 days (IQR, 61-164 days) from TB diagnosis. Although IRD was diagnosed in just 12% (n = 19) of patients overall, IRD developed in 32% (n = 12) of those who started ART within 2 months of TB diagnosis. Pulmonary involvement was observed in 84% (n = 16) and intra-abdominal manifestations were also common (37%). Overall, 4% (n = 7) of the cohort required secondary level health-care for IRD and two (1%) patients died. In multivariate analysis, risk of IRD was strongly associated with early ART initiation and low baseline CD4 cell count. Of patients with CD4 counts < 50 cells/microl, the proportions who developed IRD following initiation of ART within 0-30, 31-60, 61-90, 91-120 and > 120 days of TB diagnosis were 100%, 33%, 14%, 7% and 0%, respectively. CONCLUSIONS: The risk of TB-associated IRD in this setting is very high for those with low baseline CD4 cell counts initiating ART early in the course of antituberculosis treatment. However, most cases were self-limiting; overall secondary health-care utilization and mortality risk from IRD were low.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, HIV-positive patients with apparent sole pulmonary tuberculosis may develop peripheral or central lymphadenitis as the manifestation of IRIS [58].”
From Current diagnosis and management of peripheral tuberculous lymphadenitis. (2011) · cites this paper as [58]
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553 · cited 1×
“A majority of the global burden of HIV-associated tuberculosis (TB) lies in sub-Saharan Africa [1] and rates in southern Africa have reached almost unprecedented”
BackgroundTuberculosis in Patients with Human Immunodeficiency Virus Infection
Havlir, D. V., & Barnes, P. F. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902043400507 · Cited by 1,461 · cited 1×
“Moreover, the risks associated with TB-IRD are important variables in the debate over the optimal time for ART initiation in patients with TB [7,8,10].”
BackgroundShelburne, S. A., Visnegarwala, F., Darcourt, J., Graviss, E. A., Giordano, T. P., White, A. C., & Hamill, R. J. (2005) · AIDS · doi:10.1097/01.aids.0000161769.06158.8a · Cited by 632 · cited 3×
“In common with most previous studies [9,19,20,22,23], diagnoses of IRD were made retrospectively but were nevertheless based on systematically collected prospective data.”
BackgroundParadoxical Worsening of Tuberculosis Following Antiretroviral Therapy in Patients with AIDS
NARITA, M., ASHKIN, D., HOLLENDER, E. S., & PITCHENIK, A. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.1.9712001 · Cited by 608 · cited 2×
“patients attending referral hospitals [9,20,21,23].”
ResultLawn, S. D., Bekker, L.-G., & Miller, R. F. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70140-7 · Cited by 545 · cited 7×
“Moreover, the risks associated with TB-IRD are important variables in the debate over the optimal time for ART initiation in patients with TB [7,8,10].”
BackgroundMethodInfluentialSelf-citationParadoxical reactions during tuberculosis treatment in patients with and without HIV co-infection
Breen, R. A. M. (2004) · Thorax · doi:10.1136/thx.2003.019224 · Cited by 367 · cited 4×
“In common with most previous studies [9,19,20,22,23], diagnoses of IRD were made retrospectively but were nevertheless based on systematically collected prospective data.”
BackgroundInfluentialLawn, S. D., Myer, L., Bekker, L.-G., & Wood, R. (2006) · AIDS · doi:10.1097/01.aids.0000238406.93249.cd · Cited by 363
Self-citationLawn, S. D., Myer, L., Orrell, C., Bekker, L.-G., & Wood, R. (2005) · AIDS · doi:10.1097/01.aids.0000194802.89540.e1 · Cited by 359 · cited 3×
“reported that cryptococcal IRD is a far more common cause of death in this service [12,15].”
BackgroundMethodResultSelf-citationTreatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
Dean, G. L., Edwards, S. G., Ives, N. J., Matthews, G., Fox, E. F., Navaratne, L., Fisher, M., Taylor, G. P., Miller, R., Taylor, C. B., et al. (2002) · AIDS · doi:10.1097/00002030-200201040-00010 · Cited by 354
Cited by
Items 301–346 of 346
Otu, A. A. (2014) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2014/7963
Lawn, S. D., & Wood, R. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31819001ea
Self-citationKitabi, E. N. (2013) · Figshare
French, M. A., & Price, P. (2008) · Future HIV Therapy · doi:10.2217/17469600.2.3.263
“tuberculosis IRD are a very low CD4+ T-cell count and disseminated TB at the time the ART is commenced and a short duration of TB treatment before the ART is commenced [19].”
BackgroundTo have and have not: Dissecting Protective and Pathologic Immune Recovery in TB-IRIS
Ravimohan, S., & Bisson, G. P. (2015) · Future Virology · doi:10.2217/fvl.15.91
Running title: Management of HIV-1-TB
Schutz, C., Meintjes, G., Almajid, F. M., Wilkinson, R. J., & Pozniak, A. (2010)
Tenofovir experience from the Themba Lethu Clinic, right to care, Johannesburg.
Nyirenda, M. (2013) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Chapter 3 Future of HIV/AIDS Care in Low- and Middle- Income Countries
Hoffmann, C. J., Mills, L. A., & Gallant, J. E. (2008)
CASE STUD Y A patient with multiple IRIS
Asselman, V., & Meintjes, G. (2007)
Implementation of collaborative tuberculosis/HIV activitiesPolicy and programme issues
Getahun, H. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3988-4.00079-2
Kidanemariam, T. T. (2014) · NORA - Norwegian Open Research Archives
Tuberculosis-immune reconstitution inflammatory syndrome
Mishra, V. A., Harbada, R., Sharma, A., & Narute, S. (2014) · Journal of HIV and Human Reproduction · doi:10.4103/2321-9157.159973
“In contrast, Unmasking IRIS denotes the clinical event in which opportunistic disease, which was quiescent at the time of ART initiation, becomes clinically manifest because of ART‐induced immune recovery.[5] The pathophysiology of the syndrome is believed to involve a combination of factors, including the reconstitut…”
BackgroundBadjé, A. (2017) · theses.fr (ABES) · doi:10.70675/cedf8080zaab2z490dz91e5zca781bd0ddae · Cited by 1
Fontanella, A., Nardi, R., Masina, M., & Uomo, G. (2017) · Italian Journal of Medicine · doi:10.4081/itjm.q.2017.7
Improvement of tuberculosis diagnosis in hiv-infected children in low-income countries
Marcy, O. (2017) · theses.fr (ABES) · doi:10.70675/365ed925zc3dcz4c87z95f4z558b25b4b4de · Cited by 1
Clinical deterioration during antituberculosis treatment in a high HIV-1 prevalence setting
Pepper, D. J. (2010) · Open University of Cape Town (University of Cape Town)
Hillermann, J. (2018) · DUT Open Scholar (Durban University of Technology) · doi:10.51415/10321/3154
Patel, M. R. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/3afw-w894
Pulmonary Complications of HIV Infection
Crothers, K. A., Morris, A., & Huang, L. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00090-7 · Cited by 1
HIV/AIDS and Opportunistic Illnesses
Hoffmann, C. J., & Chaisson, R. E. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4470-3.50024-0
Systemic lymphocyte trafficking markers in TB and TB/HIV co-infections.
Pillay, K. (2019) · ResearchSpace (University of KwaZulu-Natal)
Lange, C., Manion, M. M., Lindo, N., Gorelick, R. J., Ortega‐Villa, A. M., Huik, K., Gonsalves, C., Roby, G. A., Sheikh, V., Cai, C. W., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-105550/v1
“Many newly diagnosed PWH are late presenters with advanced HIV/AIDS and CD4+ T cell counts below 100 cells/μl, who are frequently co-infected with opportunistic infections such as tuberculosis (TB) and are at substantial risk for developing immune reconstitution in ammatory syndrome (IRIS), a severe and potentially le…”
BackgroundImmune Reconstitution Inflammatory Syndrome and Hodgkin’s Lymphoma
Pivnik, A. V., Vukovich, A. M., & Petrenko, A. A. (2021) · Clinical oncohematology · doi:10.21320/2500-2139-2021-14-3-378-385
Morrison, H., Cropley, I. M., & Lipman, M. C. I. (2021) · Springer eBooks · doi:10.1007/978-3-030-75509-6_9
Clinical outcome of HIV patients who commence antiretroviral therapy at different CD4 levels
Mothapo, K. P. (2011) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Harries, A. D. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13408006.14778113
Bonnet, M., Baudin, E., Jani, I. V., Nunes, E. A., Verhoustraeten, F., Calmy, A., Bastos, R., Bhatt, N., & Michon, C. (2014) · PLoS ONE · doi:10.1371/annotation/15d01128-2495-4b95-8fe8-8702190fdb0e
Fraisse, P. (2011) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(11)70050-7
MOFENSON, L. M. (2014) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718356424.793494003
The Immune Interaction between HIV-1 Infection and Mycobacterium tuberculosis
Bruyn, E. D., & Wilkinson, R. J. (2017) · ASM Press eBooks · doi:10.1128/9781555819569.ch12 · Cited by 1
Walzl, G., van Helden, P. D., & Botha, P. R. (2014) · ASM Press eBooks · doi:10.1128/9781555816872.ch49
Hartigan-O’Connor, D. J., & Brander, C. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780197576595.003.0006
Infections sévères chez les personnes vivant avec le VIH sous l’ère des cART
Melliez, H. (2020) · theses.fr (ABES) · doi:10.70675/ff3d62f3zd2bez4fedzab88z00bf8d9c5e20
Immune Reconstitution Inflammatory Syndrome and Hodgkin’s Lymphoma
Pivnik, A., & Vukovich, A. M. (2024) · Infectious diseases · doi:10.5772/intechopen.112193
Incidence of TB-IRIS Among HIV+ve Patients in North India: A Prospective StudyPreprint
Gupta, P., Tripathi, A. K., Singh, K. P., & Gupta, A. K. (2024) · medRxiv · doi:10.1101/2024.08.06.24311589
Alharbi, A. A., Al-Arej, I. M., Alsayegh, A. S., Owias, M. I. Z. A., & Alanezi, B. S. (2019) · International Journal of Health Sciences · doi:10.53730/ijhs.v3ns1.15301
“IRIS is most likely to occur within the first 4 to 12 weeks after ART initiation [48,49], and ART can generally be continued even if IRIS develops.”
BackgroundCruz, A. T., & Starke, J. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00096-0
Hartigan-O’Connor, D. J., & Brander, C. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197812631.003.0005
Pleural Effusions in Diseases of Specific Organ Systems
Hasan, A. (2025) · Springer eBooks · doi:10.1007/978-981-96-7810-5_70
Boulle, A. (2009) · Open University of Cape Town (University of Cape Town)
Meintjes, G. (2011) · Open University of Cape Town (University of Cape Town)
Moh, D. R. (2012) · theses.fr (ABES) · doi:10.70675/6c9b4f70ze321z4121zadf2zb8b70f5dd989 · Cited by 4
“En 2009 (12), l’ONUSIDA (Programme commun des nations unies sur le VIH/SIDA) estimait à 450 000 [390 000-510 000] le nombre de personnes vivant avec le VIH en Côte d’Ivoire, ce qui permet d’estimer la prévalence récente à environ 3,4% [3,1-3,9%].”
BackgroundQiu, Y., Tang, Y., Yu, S., He, J., Wang, X., Liang, J., Li, Y., Sun, M., & Xiao, Y. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s616761 · Cited by 4
“264,265 Two distinct phenotypes of IRIS have been identified in patients with tuberculosis following ART initiation.”
Rodchenkov, A. V., Zuban, O. N., Vishnevskii, D. A., & Avdentova, V. B. (2026) · Urology reports (St - Petersburg) · doi:10.17816/uroved713789
Metadata
- Authors
- Lawn, S. D., Myer, L., Bekker, L.-G., & Wood, R.
- Affiliations
- University of Cape Town (ZA)
- Corresponding author
- Lawn, Stephen D
- Venue
- AIDS
- Published
- 2007-01-30
- Volume
- 21
- Issue
- 3
- Pages
- 335-341
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2020198464
- Cited by
- 343
- References
- 27
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 8 · 2020: 4 · 2019: 7 · 2018: 9 · 2017: 10 · 2016: 8 · 2015: 12 · 2014: 16 · 2013: 31 · 2012: 25
- FWCI
- 51.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- AIDS (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (submittedVersion)
- Funders
- Wellcome Trust (074641)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- National Institute of Allergy and Infectious Diseases (1U19 AI53217-01, AI 058736-01A1, U19AI053217, R01AI058736)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- tuberculosis, antiretroviral therapy, CD4 count, early ART initiation, risk factors, pulmonary tuberculosis, South Africa
- MeSH terms
- Adult, Antitubercular Agents, Developing Countries, Epidemiologic Methods, Female, Humans, Immune System Diseases, Inflammation, Male, South Africa, Tuberculosis, HIV Infections, AIDS-Related Opportunistic Infections, CD4 Lymphocyte Count, Anti-HIV Agents, Antiretroviral Therapy, Highly Active
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.